Loading organizations...
§ Private Profile · London, United Kingdom
AI-powered platform for managing Alzheimer's and other dementias.
Punto Health provides an AI-driven platform delivering continuous, personalized support for cognitive care. The company’s integrated system includes PuntoCare, a mobile application offering tailored daily plans, educational resources, and an AI assistant for individuals and their families. Additionally, PuntoTest utilizes speech-based digital biomarkers for early detection and remote monitoring of cognitive changes, while PuntoClinic offers healthcare providers a clinical dashboard for patient progress tracking and collaborative care coordination.
Anna Muñoz-Farré and Jack Eckersley, both engineers, founded Punto Health in 2023. The impetus for establishing the company arose from Anna Muñoz-Farré's personal experience with her grandfather’s dementia journey, which illuminated significant gaps and inefficiencies within the existing healthcare system for neurodegenerative conditions. This challenge provided the foundational insight for their solution.
The platform caters to individuals with mild cognitive impairment and dementia, their informal caregivers, as well as healthcare providers and home care organizations. Punto Health’s overarching vision is to serve as a trusted companion throughout the entire cognitive care continuum, from initial detection and assessment to ongoing support and long-term coordination, thereby enhancing the quality of life for those affected by cognitive decline.
Punto Health has raised $3.5M across 3 funding rounds.
Punto Health has raised $3.5M in total across 3 funding rounds.
Punto Health has raised $3.5M in total across 3 funding rounds.
Punto Health's investors include Enrique Linares Plaza, Abac Nest, Deuce Capital, Exceptional Ventures, Fondo Bolsa Social, Heartfelt, Lavender Ventures, Tomás Güida, Lonneke Roza, Ilonka Jankovich, Ada Ventures, Branislav Trajkovski.
Punto Health is a London-based healthtech startup founded in 2023 that builds an AI-driven, full-stack platform for early detection and personalized support in dementia and cognitive care[1][2][4]. The platform includes PuntoCare for patients with cognitive impairments (from mild to advanced dementia) and their caregivers, offering personalized care plans with cognitive exercises, activity recommendations, nutrition tips, and speech-based digital biomarkers for tracking cognitive status[2][3]. PuntoClinic provides clinician dashboards for remote monitoring, symptom tracking, and coordination between patients, carers, and healthcare professionals[3][9]. It serves patients, families, and providers in the UK and Spain, addressing gaps in post-diagnostic support like insufficient information, emotional guidance, and proactive care amid rising dementia costs (projected at £90 billion in the UK by 2040)[1][3]. Recent momentum includes a $2.7M (£2M/€2.3M) seed round in December 2025 co-led by Shilling VC and Plus Partners, plus a €100K NN Group award in June 2025, fueling product development, UK/Spain expansion, and clinical validations starting March 2025[1][7][8].
Punto Health emerged from personal experience when co-founder and CEO Anna Muñoz-Farré witnessed dementia's impact on her grandfather, revealing systemic gaps in healthcare like reactive care and lack of family support[7]. Engineers Muñoz-Farré and Jack Eckersley (motivated by neurodegenerative diseases' toll on families and systems) founded the company in London in 2023, leveraging their expertise in scalable AI systems—Muñoz-Farré from Google accel and Eckersley in robust tech builds[2][4][5]. Early traction came via co-design with patients and carers, strong NHS partnerships (e.g., Enfield and Greenwich Memory Services), and collaborations in Spain (Ace Alzheimer Center Barcelona, Hospital del Mar, Hospital General de Granollers)[1][3]. Pivotal moments include winning the €100K NN Social Innovation Award in June 2025 for proactive dementia support and securing the seed round for commercial rollout, with user Maria Rosa completing over 1,000 exercises in 8 weeks[3][7].
Punto Health rides the AI healthtech wave in neurodegenerative care, targeting dementia's explosion (78M diagnoses by 2030, 1-in-2 lifetime risk) amid aging populations and NHS digital priorities for remote, proactive support[3][7]. Timing aligns with post-diagnostic gaps—e.g., UK's £90B cost by 2040—and AI's rise for biomarkers/remote monitoring, enabling independent living and cost savings[3]. Market forces like insurer/pharma demand for scalable solutions and Europe's fragmented care systems favor its bilingual, clinician-validated approach[1][2]. It influences the ecosystem by pioneering "full-stack" dementia platforms, fostering NHS/EU collaborations, and proving AI's shift from reactive to preventive care, potentially reducing long-term burdens[1][3][8].
Punto Health is poised for rapid scale post-seed, with UK/Spain pilots proving ROI via quality-of-life boosts and cost reductions, targeting B2B then consumer expansion[2][3]. Trends like AI diagnostics, remote care mandates, and €100B+ global dementia markets will propel growth, especially with mentorship from investors like NN Group/Rubio[1][7]. Influence may evolve into a European standard-setter, integrating pharma trials and broader cognitive apps, transforming family crises into empowered management[7]. This seed momentum builds on personal origins to redefine dementia as manageable through AI.
Punto Health has raised $3.5M across 3 funding rounds. Most recently, it raised $2.7M Seed in December 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Dec 14, 2025 | $2.7M Seed | — | Enrique Linares Plaza, Abac Nest, Deuce Capital, Exceptional Ventures, Fondo Bolsa Social, Heartfelt, Lavender Ventures, Tomás Güida | Announced |
| Jun 20, 2025 | $120K Grant | Lonneke Roza, Ilonka Jankovich | — | Announced |
| May 1, 2024 | $700K Seed | — | ADA Ventures, Branislav Trajkovski, Bruce Walker, Gail Armstrong, Joan Pina, Jose Moncada Durruti, Joerg Rheinboldt | Announced |